TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02384564

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu King Vision Video Laryngoscope aBlade
Description: At time of tracheal intubation, the subject will be intubated using the Ambu King Vision Video Laryngoscope with the appropriately sized Ambu aBlade System based on manufacturer guidelines and clinical judgement. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded via direct vision. Information on subsequent attempts, time to successful intubation, and ease of tracheal tube insertion will be assessed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Laryngoscopy via Miller Straight Blade
Description: At time of tracheal intubation, the subject will be intubated via direct laryngoscopy using a straight laryngoscope blade, based on manufacturer guidelines and clinical judgement. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded via direct vision. Information on subsequent attempts, time to successful intubation, and ease of tracheal tube insertion will be assessed.
Study: NCT03571958

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BMI
Description: A derivative of motivational interviewing (MI), which is a patient-centered, collaborative counseling approach to strengthen an individual's intrinsic motivation towards a positive behavior change. BMI is intended for healthcare providers with limited time (5-10 minutes) to support a positive behavior change.
Study: NCT02160314

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pessary
Description: disposable, single-use pessary

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Absorbent pad
Study: NCT02543658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine Methylsulfate 1 MG/ML
Description: The initial dose was 1mg, intramuscular injection(IM) once every 12 hours. If there is no defecation after 12 hours, the dose is increased to 1mg IM once every 8 hours; if there is no defecation after 24 hours, the dose is increased to 1mg IM once every 6 hours. If the abdominal pressure drops below 12mmhg, neostigmine will be stopped, otherwise it will be used continuously for 7 days.

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Conservative treatment
Description: Intragastric administration of paraffin oil, 50ml,once every 8 hours；gastrointestinal decompression with nasogastric tube and rectal tub; lycerin enema promotes defecation; patients with ascites undergo percutaneous puncture drainage. Other conservative medical treatment recommended by the guidelines.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Description: Intragastric administration of paraffin oil, 50ml,once every 8 hours；gastrointestinal decompression with nasogastric tube and rectal tub; lycerin enema promotes defecation; patients with ascites undergo percutaneous puncture drainage. Other conservative medical treatment recommended by the guidelines.
Study: NCT01314989

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyproheptadine
Description: 0,25mg/kg/day orally in 2 doses per day (2mg/5 ml)for 1 month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: liquid placebo
Study: NCT03576768

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real cTBS
Description: This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham cTBS
Description: This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real iTBS
Description: This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham iTBS
Description: This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
Study: NCT00184548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eptacog alfa (activated)
Description: Sterile, freeze-dried powder in single-use vials to be reconstituted with sterile water for injection.~Three doses of 200, 100 and 100 mcg/kg to be administered bolus i.v. (intravenous) over approx. three hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eptacog alfa (activated)
Description: Sterile, freeze-dried powder in single-use vials to be reconstituted with sterile water for injection.~Three doses of 200, 100 and 100 mcg/kg to be administered bolus i.v. (intravenous) over approx. three hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT04821479

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells (MSC)
Description: Intrathecal injections of autologous bone marrow derived mesenchymal stem cells
Study: NCT02546830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeO2 v2.2 active
Description: * Automatic adjustment of oxygen through the Free O2 device.~* FreeO2 device in mode medical data collecting(SpO2,EtCO2...).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FreeO2 v2.2 with manual oxygenation
Description: * Manual adjustment of oxygen without the assistance of the FreeO2 device.~* Only FreeO2 device in mode medical data collecting(SpO2,EtCO2...).
Study: NCT01302431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manualised nurse-led telephone support
Description: The manualised nurse-led telephone support intervention is designed to provide proactive support and enable caregivers of people with multiple sclerosis manage problems encountered with caregiving
Study: NCT04292782

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anterior Quadratus lumborum block
Description: ultrasound anterior quadratum lumborum block with 1 ml/kg 0.2% ropivacaine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: caudal block
Description: ultrasound guided caudal block with 1 ml/kg 0.2% ropivacaine
Study: NCT03963154

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE)
Description: Implantation into one eye of hESC-derived RPE (Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE))
Study: NCT02673398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT00962351

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total Hip Replacement

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total Hip Replacement

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total Hip Replacement
Study: NCT02877511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987517
Description: Applied liberally to the skin (Formulation: Y73-161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen Lotion (Y65-110)
Description: Applied liberally to the skin
Study: NCT04236193

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound Shoulder and Immunological Phenotyping by FACS
Description: Cross-sectional Ultrasound exam of the affected shoulder. Peripheral blood measurements of the T and B cell subsets. Anti-Influenza Antibody measurements

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound Shoulder and Immunological Phenotyping by FACS
Description: Cross-sectional Ultrasound exam of the affected shoulder. Peripheral blood measurements of the T and B cell subsets. Anti-Influenza Antibody measurements
Study: NCT02234544

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: The groups will be randomized to ezetimibe 10 mg for 5 days or placebo. On the fifth day, they should came after an overnight fast for blood tests collection \[25(OH)D, PTH, calcium, albumin\]. Next, all participants will receive orally a cholecalciferol 50,000 IU capsule and a snack containing 15g of fat. Participants will return 14 days after that for a second blood test.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: All participants will receive orally a cholecalciferol 50,000 IU capsule and a snack containing 15g of fat. Participants will return 14 days after that for a second blood test.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cholecalciferol
Description: All participants will receive orally a cholecalciferol 50,000 IU capsule and a snack containing 15g of fat. Participants will return 14 days after that for a second blood test.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The groups will be randomized to ezetimibe 10 mg for 5 days or placebo. On the fifth day, they should came after an overnight fast for blood tests collection \[25(OH)D, PTH, calcium, albumin\]. Next, all participants will receive orally a cholecalciferol 50,000 IU capsule and a snack containing 15g of fat. Participants will return 14 days after that for a second blood test.
Study: NCT01741376

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Progesterone 200 mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02560870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator:Aloe Vera mouthwash
Description: mouthwash( Aloe Vera),10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
Study: NCT01089608

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Povidone
Description: Eye drops Single dose unit~1 drop twice daily at Day 0, then 1 drop once daily from Day 1 to Day 6 in the morning, following by a period of 2 weeks without treatment. This therapeutic scheme will be repeat 2 times.
Study: NCT01585740

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Normal Saline
Description: Crystalloid fluid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate
Description: Crystalloid fluid
Study: NCT01470963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of referral template
Description: Implementation of referral template at the GP office
Study: NCT03682861

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 20 km time trial performance
Description: 20 km time trial cycling test will be conducted to measure the effect of different drinks on time

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: 20 km time trial performance
Description: 20 km time trial cycling test will be conducted to measure the effect of different drinks on time

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Glycogen lowering exercise
Description: Glycogen will be lowered using a 10-min warm-up period at a workload of 50% max wattage power output (Wmax). Thereafter, participants will be instructed to cycle 2-min block periods at alternating workloads of 90% and 50% of Wmax, respectively. This will be continued until the participants are no longer able to complete the 2 min at 90% Wmax. That moment will be defined as the time at which the individual is unable to maintain cycling speed at 60 revolutions/min. At that moment the high-intensity block will be reduced to 80% Wmax. Again, athletes will cycle until they are unable to complete a 2-min block at 80% Wmax, after which the high-intensity block will be reduced to 70% Wmax. Finally, participants will be allowed to stop when pedalling speed could not be maintained at 70% Wmax.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Glycogen lowering exercise
Description: Glycogen will be lowered using a 10-min warm-up period at a workload of 50% max wattage power output (Wmax). Thereafter, participants will be instructed to cycle 2-min block periods at alternating workloads of 90% and 50% of Wmax, respectively. This will be continued until the participants are no longer able to complete the 2 min at 90% Wmax. That moment will be defined as the time at which the individual is unable to maintain cycling speed at 60 revolutions/min. At that moment the high-intensity block will be reduced to 80% Wmax. Again, athletes will cycle until they are unable to complete a 2-min block at 80% Wmax, after which the high-intensity block will be reduced to 70% Wmax. Finally, participants will be allowed to stop when pedalling speed could not be maintained at 70% Wmax.
Study: NCT00832611

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arteriovenous Fistula (ROX AC1)
Description: The percutaneous creation of an arteriovenous fistula.
Study: NCT02931084

Intervention type: OTHER
Intervention: Rehabilitation
Description: In line with current treatment guidelines, patients will undergo rehabilitation for at least the first three months, before a decision regarding ACL reconstruction is taken

Intervention type: OTHER
Intervention: Rehabilitation
Description: In line with current treatment guidelines, patients will undergo rehabilitation for at least the first three months, before a decision regarding ACL reconstruction is taken
Study: NCT02560870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator:Chlorhexidine mouthwash
Description: mouthwash( Chlorhexidine ),10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
Study: NCT02931084

Intervention type: PROCEDURE
Intervention: ACL reconstruction
Description: Approximately half of the patients will have ACL-reconstruction after an initial time of rehabilitation
Study: NCT03521115

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smart Choices 4 Teens
Description: This is a web-based prevention program designed to convey information about alcohol and relationships and the types of choices that they are making regarding these topics. General communications was another core element of the program that provided parents and teens with some key elements of talking to each other.
Study: NCT02968693

Intervention type: DEVICE
Intervention: antibiotic-loaded calcium sulfate
Description: To obtain a paste suitable for pellets, the following steps should be used: 1. Empty 10 cc Stimulan® calcium sulfate powder (Stimulan; Biocomposites Ltd; United Kingdom) into a sterile mixing bowl. 2. The calcium sulfate powder was mixed with 2,000 mg of vancomycin powder. 3. Add approximately 5 ml mixing solution into the above mixture. Mix thoroughly until a smooth paste is formed (approximately 30 seconds). 4. The resultant paste is uniformly smooth into the mould provided to form pellets with diameters of 4.8 mm and height of 3.3 mm. 5. Allow paste to cure undisturbed for at least 15 minutes after mixing. Flex mould to release pellets.

Intervention type: DEVICE
Intervention: antibiotic-loaded polymethyl methacrylate
Description: One sachet of 40g PALACOSR®+G power containing 33.6g PMMA and with the addition of 0.5g gentamicin sulphate (Heraeus Medical Gesellschaft mit beschränkter Haftung,Germany) was mixed with 4,000 mg of vancomycin powder in a sterile bowl. The liquid provided was poured into the resultant mixture above. Then, the mixture was stirred carefully for 30 sec. If the dough-like mass no longer sticked to the rubber gloves, it can be progressed. If the required consistency was obtained, the cement can be applied to the bony defect until it hardened completely.

Intervention type: DEVICE
Intervention: antibiotic-loaded polymethyl methacrylate
Description: One sachet of 40g PALACOSR®+G power containing 33.6g PMMA and with the addition of 0.5g gentamicin sulphate (Heraeus Medical Gesellschaft mit beschränkter Haftung,Germany) was mixed with 4,000 mg of vancomycin powder in a sterile bowl. The liquid provided was poured into the resultant mixture above. Then, the mixture was stirred carefully for 30 sec. If the dough-like mass no longer sticked to the rubber gloves, it can be progressed. If the required consistency was obtained, the cement can be applied to the bony defect until it hardened completely.

Intervention type: DRUG
Intervention: Vancomycin
Description: Vancomycin powder was added into the combination therapy group and PMMA groups

Intervention type: DRUG
Intervention: Vancomycin
Description: Vancomycin powder was added into the combination therapy group and PMMA groups
Study: NCT03672838

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: hand-held dynamometer
Description: Strength of one weak muscle group and of the biceps of the dominant arm will be measured using a hand-held dynamometer. An average of three readings will be used as one observation. Three observations per patient will be obtained on one day with a minimum of 15 minute rest period between each observation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: hand-held dynamometer
Description: Strength of one weak muscle group and of the biceps of the dominant arm will be measured using a hand-held dynamometer. An average of three readings will be used as one observation. Three observations per patient will be obtained on one day with a minimum of 15 minute rest period between each observation.
Study: NCT01483729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: Phase 3 Tablet Formulation 1, single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: Phase 3 Tablet Formulation 2, single oral dose
Study: NCT04318184

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: The aerobic exercise protocol was performed 3 times a week for 3 months on the treadmill. Loading periods were performed according to the heart rate maximum using the Karvonen formula (%60-80 Heart rate maximum)
Study: NCT01483729

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: danoprevir
Description: Reference Phase 2 Tablet Formulation, single oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: danoprevir
Description: Reference Phase 2 Tablet Formulation, single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: Reference Phase 2 Tablet Formulation, single oral dose
Study: NCT03012464

Intervention type: OTHER
Intervention: Pathologic and functional assessment
Description: Random biopsies will be taken from the pelvic floor muscles, external anal sphincter, and the lateral supportive ligaments of the rectum during surgical treatment of rectal prolapse whether via the abdominal or perineal approach. Tissue samples will be subjected to immunohistochemistry to calculate the ratio between collagen type I and type III, and to reveal any myopathic or degenerative changes
Study: NCT01483729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: Reference Phase 2 Tablet Formulation, single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: Test Formulation 1, single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: Test Formulation 2, single oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir
Description: Reference Formulation, single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: Reference Formulation, single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: Reference Formulation, single oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir
Description: Reference Formulation, single oral dose
Study: NCT00434174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: RAD001 will be supplied by Novartis as tablets in 3 different dosage strengths, 2.5, 5 and 10 mg. All proposed dose levels in this study can be given as a combination of these dose strengths.~Daily doses of 2.5, 5, 7.5 and 10 mg of RAD001 will be given alongside the standard 21-day cycle of pemetrexed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: RAD001 will be supplied by Novartis as tablets in 3 different dosage strengths, 2.5, 5 and 10 mg. All proposed dose levels in this study can be given as a combination of these dose strengths.~Daily doses of 2.5, 5, 7.5 and 10 mg of RAD001 will be given alongside the standard 21-day cycle of pemetrexed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed was supplied to the sites in 500 mg/m2 was administered on Day 1 of each cycle as a 10-minute continuous i.v. infusion in 100mL normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed was supplied to the sites in 500 mg/m2 was administered on Day 1 of each cycle as a 10-minute continuous i.v. infusion in 100mL normal saline
Study: NCT02880865

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated SA 14-14-2 Japanese Encephalitis vaccine
Description: Single 0.5 mL dose of World Health Organization prequalified live, attenuated SA 14-14-2 JE vaccine manufactured by Chengdu Institute of Biological Products, Chengdu, China, administered by subcutaneous injection
Study: NCT01060774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Up to 5 capsules of 2% lidocaine with epinephrine as a reinforcement drug post-operatively
Study: NCT00448786

Intervention type: DRUG
Group type: OTHER
Intervention: AMG 706
Description: Arm B - AMG 706 75 mg BID 2-weeks on and 1-week off
Study: NCT00791206

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real preconditioning
Description: Preconditioning will consist of four 5 minutes cycles of upper limb ischemia interspaced with 5 minutes of reperfusion, using a blood-pressure cuff inflated to a pressure 15 mmHg greater than systolic arterial pressure.
Study: NCT02880865

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, mumps, rubella vaccine
Description: Single 0.5 mL dose of live, attenuated measles-mumps-rubella vaccine (Schwarz measles virus, RIT 4385 mumps strain, and Wistar RA 27/3 rubella virus) manufactured by GlaxoSmithKline, Inc., administered by subcutaneous injection.
Study: NCT00448786

Intervention type: DRUG
Group type: OTHER
Intervention: AMG 706
Description: Arm C - 75 mg BID 5-days on, 2-days off
Study: NCT00791206

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sham preconditioning
Description: Preconditioning will consist of four 5 minutes cycles of upper limb ischemia interspaced with 5 minutes of reperfusion, using a blood-pressure cuff inflated to a pressure 10mmHg with the same cycling protocol as the real preconditioning.